Furiex Pharmaceuticals

About:

Furiex Pharmaceuticals is a drug development collaboration company focused on improving the value of partnered drug programs.

Website: http://furiex.com

Twitter/X: allergan

Top Investors: Fred Eshelman

Description:

Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections.